JP2022547452A5 - - Google Patents

Info

Publication number
JP2022547452A5
JP2022547452A5 JP2022513902A JP2022513902A JP2022547452A5 JP 2022547452 A5 JP2022547452 A5 JP 2022547452A5 JP 2022513902 A JP2022513902 A JP 2022513902A JP 2022513902 A JP2022513902 A JP 2022513902A JP 2022547452 A5 JP2022547452 A5 JP 2022547452A5
Authority
JP
Japan
Prior art keywords
sequence
seq
composition according
antibody
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022513902A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547452A (ja
JP7663559B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/058114 external-priority patent/WO2021044287A1/en
Publication of JP2022547452A publication Critical patent/JP2022547452A/ja
Publication of JP2022547452A5 publication Critical patent/JP2022547452A5/ja
Application granted granted Critical
Publication of JP7663559B2 publication Critical patent/JP7663559B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022513902A 2019-09-03 2020-09-01 Actrii受容体拮抗薬を含む肝疾患または肝臓障害の治療 Active JP7663559B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962895107P 2019-09-03 2019-09-03
US62/895,107 2019-09-03
PCT/IB2020/058114 WO2021044287A1 (en) 2019-09-03 2020-09-01 Treatment of liver disease or disorder comprising actrii receptor antagonists

Publications (3)

Publication Number Publication Date
JP2022547452A JP2022547452A (ja) 2022-11-14
JP2022547452A5 true JP2022547452A5 (cg-RX-API-DMAC7.html) 2025-01-15
JP7663559B2 JP7663559B2 (ja) 2025-04-16

Family

ID=72422213

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022513902A Active JP7663559B2 (ja) 2019-09-03 2020-09-01 Actrii受容体拮抗薬を含む肝疾患または肝臓障害の治療

Country Status (12)

Country Link
US (1) US20220340668A1 (cg-RX-API-DMAC7.html)
EP (1) EP4025248A1 (cg-RX-API-DMAC7.html)
JP (1) JP7663559B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220054608A (cg-RX-API-DMAC7.html)
CN (1) CN114630681A (cg-RX-API-DMAC7.html)
AU (1) AU2020341135A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022003884A2 (cg-RX-API-DMAC7.html)
CA (1) CA3153062A1 (cg-RX-API-DMAC7.html)
IL (1) IL290852A (cg-RX-API-DMAC7.html)
JO (1) JOP20220057A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022002636A (cg-RX-API-DMAC7.html)
WO (1) WO2021044287A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
EP4577301A1 (en) * 2022-08-26 2025-07-02 Versanis Bio, Inc. Actrii antibody fixed unit dose treatments
CN117577330B (zh) * 2024-01-15 2024-04-02 北京大学 预测非酒精性脂肪性肝病肝纤维化程度的装置及存储介质
WO2025183966A1 (en) 2024-02-28 2025-09-04 Versanis Bio, Inc. Actrii antibodies with extended half life
WO2026128614A1 (en) * 2024-12-10 2026-06-18 Supercede Therapeutics, Inc. Activin receptor type ii inhibitors for preventing or treating obesity and related disorders

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050186593A1 (en) 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
ES2330062T3 (es) 1998-05-06 2009-12-03 Metamorphix, Inc. Procedimientos para tratar la diabetes por inhibicion de gdf-8.
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ActRII受容体ポリペプチド、方法、および組成物
ES2655877T3 (es) 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
EP3260130B1 (en) * 2009-11-03 2021-03-10 Acceleron Pharma Inc. Methods for treating fatty liver disease
KR101461706B1 (ko) * 2011-04-04 2014-11-18 한국생명공학연구원 Dlk1 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2b 억제제
CN104513213A (zh) 2013-09-28 2015-04-15 山东亨利医药科技有限责任公司 Fxr激动剂
CA2942403A1 (en) 2014-03-13 2015-09-17 Salk Institute For Biological Studies Fxr agonists and methods for making and using
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
CA2968434A1 (en) 2014-11-21 2016-05-26 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
RU2741387C2 (ru) 2014-12-22 2021-01-25 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
WO2017078928A1 (en) 2015-11-06 2017-05-11 Salk Institute For Biological Studies Fxr agonists and methods for making and using
CN106946867B (zh) 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
WO2017128896A1 (zh) 2016-01-26 2017-08-03 江苏豪森药业集团有限公司 Fxr激动剂及其制备方法和应用
WO2017143134A1 (en) 2016-02-19 2017-08-24 Alios Biopharma, Inc. Fxr modulators and methods of their use
KR20180128405A (ko) 2016-02-22 2018-12-03 악셀레론 파마 인코포레이티드 면역 활성 증가에 사용하기 위한 ActRII 길항제
US10080743B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017201152A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
US10183872B2 (en) 2016-06-13 2019-01-22 Qi Wang Counter circulating liquid processing system by repeatedly re-using thermal energy
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
WO2018039384A1 (en) 2016-08-23 2018-03-01 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators
CN108430998B (zh) 2016-09-28 2021-07-09 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
CA3039124A1 (en) 2016-10-04 2018-04-12 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
CN107973790A (zh) 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
WO2018081285A1 (en) 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
CN108017636A (zh) 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
JOP20190152A1 (ar) 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
CN109071468B (zh) 2017-01-20 2022-09-02 四川科伦博泰生物医药股份有限公司 一种杂环化合物及其制备方法和用途
WO2018190643A1 (en) 2017-04-12 2018-10-18 Il Dong Pharmaceutical Co., Ltd. An isoxazole derivatives as nuclear receptor agonists and used thereof
CA3064794A1 (en) 2017-05-26 2018-11-29 Medshine Discovery Inc. Lactam compound as fxr receptor agonist
US11352358B2 (en) 2017-07-06 2022-06-07 Xuanzhu Biopharmaceutical Co., Ltd. FXR agonist
CN109053751A (zh) 2018-08-30 2018-12-21 成都海博锐药业有限公司 具有螺环结构的fxr调节剂

Similar Documents

Publication Publication Date Title
JP7266530B2 (ja) エラフィブラノールのようなPPARアゴニスト及びアセチルCoAカルボキシラーゼ(ACC)を含む組合せ
WO2023280152A1 (en) Combination therapy for treatment of liver diseases
AU2020203316B2 (en) Novel regimes of FXR agonists
RU2471483C2 (ru) Противоопухолевые комбинации, содержащие ингибитор vegf и иринотекан
CN115461072A (zh) 用于治疗非酒精性脂肪性肝炎的司美格鲁肽
WO2021044287A1 (en) Treatment of liver disease or disorder comprising actrii receptor antagonists
AU2020201980A1 (en) Combination of FXR agonists
JP2023507364A (ja) インテグリン阻害剤を使用する肝疾患の治療の組み合わせ
CN117915914A (zh) 治疗肝病的组合疗法
JP2021529766A5 (cg-RX-API-DMAC7.html)
CN109432431A (zh) 一种含有sumo抑制剂的组合物及应用
JP2022549066A5 (cg-RX-API-DMAC7.html)
JP2025508852A (ja) 環状ホスホネート組成物およびその調製方法
CA3100635A1 (en) Combinations comprising tropifexor and cenicriviroc
JP2022522873A5 (cg-RX-API-DMAC7.html)
US12559553B2 (en) IL-31 modulators for treating FXR-induced pruritus
RU2022104049A (ru) Комбинированное лечение заболеваний печени агонистами fxr
Sumida et al. An eBook on Diabetes
Prous Annual Update 2004/2005-Treatment of gastrointestinal disorders
Martin et al. Pemphigus